Sources
Genetic Engineering & Biotechnology NewsStockWatch: Biogen's Q4 Results Disappoint Analysts Biogen’s stock price fell 10.5% this past week as sales of key drugs, as well as fourth quarter earnings and revenue missed expectations. Learn more: https://t.co/itp8AkdDde https://t.co/qgMhVLKsue
Market Rebellion$CZR Q4 Earnings Sales: $2.83B misses $2.85B estimates EPS: $(0.34) misses $(0.07) estimates Shares are nearly flat around $41.40 in after hours trading following the double miss.
Market Rebellion$TDOC Q4 Earnings Sales: $660.5 misses $671.43 estimate EPS: $(0.17) beats $(0.21) estimate Shares currently down 🔴 -10% to $18.26 in after hours trading.
Additional media







